Drug Safety Board Is Biased By Connection To CDER, Sen. Grassley Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Grassley is asking FDA to outline the specific steps that will be taken to ensure the independence of the committee. A letter to FDA Acting Commissioner Crawford was released the same day the Institute of Medicine convened its meeting to study FDA’s drug safety review practices.